VERA · Vera Therapeutics, Inc.

Vera Therapeutics reported significantly wider losses in Q1 FY2026, with operating income at -$125.1 million versus -$57.2 million in Q1 FY2025, a 118.8% deterioration. This expansion stems from the company's strategic focus on advancing its lead asset atacicept for IgAN, necessitating substantial investments in clinical trials and related operations. Net income followed suit at -$121.0 million, compared to -$51.7 million last year (-134.1% YoY), with diluted EPS declining to -$1.69 from -$0.81 (-108.6%). These results highlight the capital-intensive nature of biotech development, where prior and expected future losses continue to pressure working capital but align with management's commitment to pipeline progression.

Cash utilization intensified, with net cash provided by operating activities at -$106.5 million, up from -$54.4 million YoY, and free cash flow at -$106.5 million after $23 thousand in capital expenditures (down from $187 thousand). This accelerated burn reflects the ramp-up in development activities, including milestone-related outflows inherent to license agreements and clinical execution. Management notes that switching or adding CROs could further elevate costs and divert focus, underscoring the operational discipline required to manage these expenditures effectively.